@article{TCR18035,
author = {Carlos Rojas and Vamsidhar Velcheti},
title = {Checkpoint inhibitors after chemoradiation: is it ready for prime time?},
journal = {Translational Cancer Research},
volume = {7},
number = {Suppl 1},
year = {2017},
keywords = {},
abstract = {Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the United States (1). About a third of the patients diagnosed with NSCLC are diagnosed at a locally advanced stage (stage III). Despite concurrent chemoradiation, the outcome for patients diagnosed with locally advanced NSCLC is very poor with a 5-year survival of },
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/18035}
}